Cargando…
P1115: A MULTICENTER PHASE 1/2 TRIAL OF EO2463, A MICROBIAL-DERIVED PEPTIDE THERAPEUTIC VACCINE, AS MONOTHERAPY AND IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB, FOR TREATMENT OF PATIENTS WITH INDOLENT NHL
| Autores principales: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429576/ http://dx.doi.org/10.1097/01.HS9.0000847328.48663.29 |
| _version_ | 1784779498623860736 |
|---|---|
| author | Zinzani, P. L. Ansell, S. M. Bosch, F. Friedberg, J. W. Marolleau, J. P. Arcaini, L. Garcia-Sanz, R. Gopal, A. K. Grande, C. Merryman, R. Pinto, A. Smith, S. D. Villasboas, J. C. Wallace, D. Fagerberg, J. Magalhaes, J. G. Armand, P. |
| author_facet | Zinzani, P. L. Ansell, S. M. Bosch, F. Friedberg, J. W. Marolleau, J. P. Arcaini, L. Garcia-Sanz, R. Gopal, A. K. Grande, C. Merryman, R. Pinto, A. Smith, S. D. Villasboas, J. C. Wallace, D. Fagerberg, J. Magalhaes, J. G. Armand, P. |
| author_sort | Zinzani, P. L. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9429576 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94295762022-08-31 P1115: A MULTICENTER PHASE 1/2 TRIAL OF EO2463, A MICROBIAL-DERIVED PEPTIDE THERAPEUTIC VACCINE, AS MONOTHERAPY AND IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB, FOR TREATMENT OF PATIENTS WITH INDOLENT NHL Zinzani, P. L. Ansell, S. M. Bosch, F. Friedberg, J. W. Marolleau, J. P. Arcaini, L. Garcia-Sanz, R. Gopal, A. K. Grande, C. Merryman, R. Pinto, A. Smith, S. D. Villasboas, J. C. Wallace, D. Fagerberg, J. Magalhaes, J. G. Armand, P. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9429576/ http://dx.doi.org/10.1097/01.HS9.0000847328.48663.29 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Zinzani, P. L. Ansell, S. M. Bosch, F. Friedberg, J. W. Marolleau, J. P. Arcaini, L. Garcia-Sanz, R. Gopal, A. K. Grande, C. Merryman, R. Pinto, A. Smith, S. D. Villasboas, J. C. Wallace, D. Fagerberg, J. Magalhaes, J. G. Armand, P. P1115: A MULTICENTER PHASE 1/2 TRIAL OF EO2463, A MICROBIAL-DERIVED PEPTIDE THERAPEUTIC VACCINE, AS MONOTHERAPY AND IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB, FOR TREATMENT OF PATIENTS WITH INDOLENT NHL |
| title | P1115: A MULTICENTER PHASE 1/2 TRIAL OF EO2463, A MICROBIAL-DERIVED PEPTIDE THERAPEUTIC VACCINE, AS MONOTHERAPY AND IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB, FOR TREATMENT OF PATIENTS WITH INDOLENT NHL |
| title_full | P1115: A MULTICENTER PHASE 1/2 TRIAL OF EO2463, A MICROBIAL-DERIVED PEPTIDE THERAPEUTIC VACCINE, AS MONOTHERAPY AND IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB, FOR TREATMENT OF PATIENTS WITH INDOLENT NHL |
| title_fullStr | P1115: A MULTICENTER PHASE 1/2 TRIAL OF EO2463, A MICROBIAL-DERIVED PEPTIDE THERAPEUTIC VACCINE, AS MONOTHERAPY AND IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB, FOR TREATMENT OF PATIENTS WITH INDOLENT NHL |
| title_full_unstemmed | P1115: A MULTICENTER PHASE 1/2 TRIAL OF EO2463, A MICROBIAL-DERIVED PEPTIDE THERAPEUTIC VACCINE, AS MONOTHERAPY AND IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB, FOR TREATMENT OF PATIENTS WITH INDOLENT NHL |
| title_short | P1115: A MULTICENTER PHASE 1/2 TRIAL OF EO2463, A MICROBIAL-DERIVED PEPTIDE THERAPEUTIC VACCINE, AS MONOTHERAPY AND IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB, FOR TREATMENT OF PATIENTS WITH INDOLENT NHL |
| title_sort | p1115: a multicenter phase 1/2 trial of eo2463, a microbial-derived peptide therapeutic vaccine, as monotherapy and in combination with lenalidomide and rituximab, for treatment of patients with indolent nhl |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429576/ http://dx.doi.org/10.1097/01.HS9.0000847328.48663.29 |
| work_keys_str_mv | AT zinzanipl p1115amulticenterphase12trialofeo2463amicrobialderivedpeptidetherapeuticvaccineasmonotherapyandincombinationwithlenalidomideandrituximabfortreatmentofpatientswithindolentnhl AT ansellsm p1115amulticenterphase12trialofeo2463amicrobialderivedpeptidetherapeuticvaccineasmonotherapyandincombinationwithlenalidomideandrituximabfortreatmentofpatientswithindolentnhl AT boschf p1115amulticenterphase12trialofeo2463amicrobialderivedpeptidetherapeuticvaccineasmonotherapyandincombinationwithlenalidomideandrituximabfortreatmentofpatientswithindolentnhl AT friedbergjw p1115amulticenterphase12trialofeo2463amicrobialderivedpeptidetherapeuticvaccineasmonotherapyandincombinationwithlenalidomideandrituximabfortreatmentofpatientswithindolentnhl AT marolleaujp p1115amulticenterphase12trialofeo2463amicrobialderivedpeptidetherapeuticvaccineasmonotherapyandincombinationwithlenalidomideandrituximabfortreatmentofpatientswithindolentnhl AT arcainil p1115amulticenterphase12trialofeo2463amicrobialderivedpeptidetherapeuticvaccineasmonotherapyandincombinationwithlenalidomideandrituximabfortreatmentofpatientswithindolentnhl AT garciasanzr p1115amulticenterphase12trialofeo2463amicrobialderivedpeptidetherapeuticvaccineasmonotherapyandincombinationwithlenalidomideandrituximabfortreatmentofpatientswithindolentnhl AT gopalak p1115amulticenterphase12trialofeo2463amicrobialderivedpeptidetherapeuticvaccineasmonotherapyandincombinationwithlenalidomideandrituximabfortreatmentofpatientswithindolentnhl AT grandec p1115amulticenterphase12trialofeo2463amicrobialderivedpeptidetherapeuticvaccineasmonotherapyandincombinationwithlenalidomideandrituximabfortreatmentofpatientswithindolentnhl AT merrymanr p1115amulticenterphase12trialofeo2463amicrobialderivedpeptidetherapeuticvaccineasmonotherapyandincombinationwithlenalidomideandrituximabfortreatmentofpatientswithindolentnhl AT pintoa p1115amulticenterphase12trialofeo2463amicrobialderivedpeptidetherapeuticvaccineasmonotherapyandincombinationwithlenalidomideandrituximabfortreatmentofpatientswithindolentnhl AT smithsd p1115amulticenterphase12trialofeo2463amicrobialderivedpeptidetherapeuticvaccineasmonotherapyandincombinationwithlenalidomideandrituximabfortreatmentofpatientswithindolentnhl AT villasboasjc p1115amulticenterphase12trialofeo2463amicrobialderivedpeptidetherapeuticvaccineasmonotherapyandincombinationwithlenalidomideandrituximabfortreatmentofpatientswithindolentnhl AT wallaced p1115amulticenterphase12trialofeo2463amicrobialderivedpeptidetherapeuticvaccineasmonotherapyandincombinationwithlenalidomideandrituximabfortreatmentofpatientswithindolentnhl AT fagerbergj p1115amulticenterphase12trialofeo2463amicrobialderivedpeptidetherapeuticvaccineasmonotherapyandincombinationwithlenalidomideandrituximabfortreatmentofpatientswithindolentnhl AT magalhaesjg p1115amulticenterphase12trialofeo2463amicrobialderivedpeptidetherapeuticvaccineasmonotherapyandincombinationwithlenalidomideandrituximabfortreatmentofpatientswithindolentnhl AT armandp p1115amulticenterphase12trialofeo2463amicrobialderivedpeptidetherapeuticvaccineasmonotherapyandincombinationwithlenalidomideandrituximabfortreatmentofpatientswithindolentnhl |